Alvotech
http://www.alvotech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alvotech
Alvotech Willing And Able To Go Stride For Stride On Pembrolizumab Manufacturing
Alvotech stepped into its 2023 annual financing results call bursting with positive news and momentum, on the back of obtaining USFDA approval for its biosimilar Humira product and a bullish outlook for its strong pipeline of biosimilar candidates.
Aurobindo One Step Closer To Xolair Biosimilar Registration
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
Biosimilar Interchangeability Designation Would Be Nixed Under Biden Proposal
The proposal is not expected to cost or save the government money, but is expected to increase biosimilar uptake, according to budget documents.
Alvotech Sees Opportunities Open Up With US Approvals
With long-awaited US approvals now rolling in and a growing pipeline of future biosimilars, further opportunities are opening up for Alvotech – including potentially launching a second interchangeable Stelara biosimilar in the US just a few months after market formation – chief commercial officer Anil Okay and chief strategy officer Ming Li tell Generics Bulletin.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alvotech Iceland
- Alvotech Germany GmnH
- Alvotech Swiss AG
- Glycothera
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice